logo-loader

Allergy Therapeutics to sniff out more M&A deals, says CEO

Published: 00:14 22 Sep 2015 AEST

Manuel Llobert, chief executive of Allergy Therapeutics (LON:AGY), says the firm is far better placed to make acquisitions given the recent increase in its market value.

Shares in the allergy prevention are specialist up 28% in the last six months and Llobert says the company will likely add to its purchase of Spain’s Alerpharma earlier this year.

It comes as revenues from the maker of the Pollinex range of vaccines rose by 11% to £46.6mln in the year to June.

The rise, according to the CEO, is down to a “well-accepted portfolio” containing the “most convenient products" in the market.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

10 hours, 24 minutes ago